FDA Accepts BLA for Advanced Melanoma Therapy

Share this content:
FDA Accepts BLA for Advanced Melanoma Therapy
FDA Accepts BLA for Advanced Melanoma Therapy

Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-3475, an investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. The FDA has also granted Priority Review to the BLA.

The MK-3475 development program is currently ongoing in 30 tumor types as monotherapy and in combination. It is anticipated that by the end of 2014, the MK-3475 development program will grow to more than 24 clinical trials across 30 different tumor types, enrolling an estimated 6,000 patients, including four new Phase 3 studies.

RELATED: Skin Cancer Resource Center

Ongoing and planned late-stage monotherapy and combination studies include seven Phase 3 registrational trials with advanced melanoma (adjuvant, ipilimumab-naïve, and ipilimumab-refractory), advanced non-small cell lung cancer (NSCLC) (previously-treated and previously-untreated), advanced head & neck cancer and advanced bladder cancer; and ten combination studies, including advanced melanoma, advanced NSCLC, advanced renal cell carcinoma, HER2+ breast cancer and other solid tumors.

Previously, the FDA had granted MK-3475 Breakthrough Therapy designation for advanced melanoma. If approved, MK-3475 would be the first anti-PD-1 antibody in a new class of immune checkpoint modulators.

For more information call (800) 672-6372 or visit Merck.com.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs